Research programme: Alzheimer's disease therapy - Thuris/D-Pharm

Drug Profile

Research programme: Alzheimer's disease therapy - Thuris/D-Pharm

Alternative Names: Alzheimer's disease therapy research programme - Thuris/D-Pharm

Latest Information Update: 28 Jul 2004

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Thuris Corporation
  • Class Ethylenediamines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 28 Jul 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 03 Sep 2002 Preclinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top